| 267 | 11 | 40 |
| 下载次数 | 被引频次 | 阅读次数 |
目的评价国产那格列奈片治疗2型糖尿病的有效性和安全性。方法采用随机对照双盲双模拟临床试验方法,收集60例2型糖尿病患者,随机分为试验组30例,口服那格列奈片120 mg,tid;对照组30例,口服国产瑞格列奈片1 mg,tid,经2wk平衡期后进入治疗期,疗程12 wk。结果与用药前比较,治疗12 wk时,2组空腹血糖均下降,但无统计学意义;2组PBG治疗后与治疗前相比,差异有显著意义(P<0.05)。那格列奈组餐后1 h胰岛素增加,与治疗前相比有统计学意义。结论那格列奈120 mg,tid与瑞格列奈片1 mg,tid降低FBG疗效相当,国产那格列奈能有效降低患者PBG及HbA1c。
Abstract：AIM To evaluate efficacy and safety of domestic nateglinide tablet in comparison with domestic repaglinide in type 2 diabetic patients.METHODS Sixty type 2 diabetic patients were randomly assigned to therapy group(domestic nateglinide,120 mg tid,n=30) and control group(domestic repaglinide,1 mg tid,n=30).The trial consisted of 2 wk equilibrated period followed by 12 wk treatment course.RESULTS The mean of fasting blood glucose(FBG) in both 2 groups were decreased duration at wk 12,but there was no statistically significant difference between 2 groups(P>0.05);The mean of postprandial blood glucose(PBG) were reduced in therapy group and control group.There was statistically significant difference of PBG between 2 groups(P<0.05).CONCLUSION The effect of nateglinide 120 mg,tid equals to repaglinide 1 mg,tid in type 2 diabetes mellitus.Nateglinide can reduce PBG and HbA1c effectively.
[1]Barnett AH,Anderson DM,Shelley S,et al.A placebo-controlledcrossover study comparing the effects of nateglinide and glibenclamide onpostprandial hyperglycaemia and hyperinsulinaemia in patients with type2 diabetes[J].Diabetes Obes Metab,2004,6(2):104.
[2]McLeod JF.Clinical pharmacokinetics of nateglinide:a rapidly-ab-sorbed,short-acting insulinotropic agent[J].Clin Pharmacokinet,2004,43(2):97.
[3]Hu SL,Wang SH,Fanelli B,et al.Pancreatic-βcells K-ATP channel ac-tively and membrane-blinding studies with nateglinide:A comparison withsulfonyureas and repaglinide[J].J Pharmaco Exp Ther,2000,293:444.
[4]Fonseca V,Kelley D,Cefalu W,et al.Hypoglycemic potential ofnateglinide versus glyburide in patients with type 2 diabetes mellitus[J].Metabolism,2004,53(10):1331.
[5]Li JW,Tian HM,Yu HL,et al.Comparison of efficacy betweennateglinide and repaglinide in treating type 2 diabetes:a randomizedcontrolled double-blind clinical trial[J].Sichuan Da Xue Xue Bao YiXue Ban,2005,36(2):267.
基本信息:
DOI：10.19577/j.cnki.issn10074406.2006.02.005
中图分类号:R587.1
引用信息:
[1]罗佐杰,谢新荣,秦映芬,等.那格列奈治疗2型糖尿病的有效性与安全性[J].中国临床药学杂志,2006(02):80-83.DOI:10.19577/j.cnki.issn10074406.2006.02.005.
2006-03-25
2006-03-25